Minerva Neurosciences | NERV - Equity Capital And Reserves


Minerva Neurosciences reported $-140.75M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.31B 58.54M Jun/2026
Adma Biologics USD 408.21M 17.88M Jun/2026
ALKERMES USD 1.81B 57.02M Jun/2026
Alterity Therapeutics Limited AUD 36.21M 18.58M Dec/2025
AstraZeneca USD 50.3B 2.96B Jun/2026
BioCryst Pharmaceuticals USD -454.29M 99.55M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Cipla INR 344.32B 15.13B Mar/2026
Clal Biotechnology ILS 121.41M 4.62M Dec/2023
Compugen USD 95.35M 7.38M Mar/2026
CSL USD 18.66B 2.75B Dec/2025
Eli Lilly USD 33.88B 2.68B Jun/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
Grifols EUR 6.21B 133.12M Dec/2025
Halozyme Therapeutics USD 143.54M 76.09M Jun/2026
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
J&J USD 84.97B 3.78B Jun/2026
Merck USD 41.93B 3.94B Jun/2026
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Neurocrine Biosciences USD 3.69B 286.2M Jun/2026
Novartis USD 41.95B 3.02B Jun/2026
Novavax USD -190.71M 45.94M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sanofi EUR 69.57B 3.24B Jun/2026
Takeda JPY 7.56T 215.7B Jun/2026
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025